Renaissance Capital logo

In need of a doctor: Visterra, a vaccine biotech, postpones $50 million IPO

February 9, 2017
VIST

Visterra, which is developing vaccines for influenza A, Dengue, Zika and multiple myeloma, postponed its IPO on Thursday, citing market conditions. It had filed to raise $50 million by offering 3.9 million shares at a price range of $12 to $14.

The Cambridge, MA-based company was founded in 2007 and booked $15 million in sales for the 12 months ended September 30, 2016. It had planned to list on the Nasdaq under the symbol VIST. Leerink Partners and Stifel were set to be the joint bookrunners on the deal.